MedImmune

MedImmune to close vaccines sites in California

Tuesday, July 17, 2012 02:55 PM

Gaithersburg, Md.-based MedImmune, the global biologics arm of AstraZeneca, is restructuring its infectious disease and vaccines research, development and operations, closing its Mountain View, Calif., and Santa Clara, Calif., sites and consolidating its infectious disease and vaccines R&D to other existing sites. The changes are expected to be completed in 2014.

More... »

Axerion, AstraZeneca collaborate on biologic treatment approach for Alzheimer's

Wednesday, May 2, 2012 10:06 AM

Axerion Therapeutics, a private Connecticut-based biotech, and MedImmune, the global biologics arm of AstraZeneca, have entered into a research collaboration and sublicense arrangement to develop and commercialize a biologic approach for the treatment of Alzheimer's disease.

More... »

AstraZeneca commits additional $100m to MedImmune

Tuesday, November 29, 2011 02:22 PM

AstraZeneca has committed an additional $100 million to its venture capital arm, MedImmune Ventures, increasing the total capital under management to $400 million. MedImmune Ventures is an evergreen venture capital fund that focuses on equity investments in private companies in the areas of biopharmaceuticals, medical and healthcare technology.

More... »

U-M Medical School, MedImmune ink 3 year research agreement

Wednesday, November 23, 2011 09:42 AM

Leaders from the University of Michigan Medical School and MedImmune, the global biologics arm of AstraZeneca, have signed a new agreement to work together on a broad range of projects. The three-year strategic collaboration will bring scientists from one of the nation’s top medical research institutions together with scientists from one of the world’s leading developers of biologic therapies. UMMS and MedImmune scientists will cooperate on studies that aim to translate scientific discoveries from the laboratory into new candidates for treating cancer, heart disease, digestive disease, lung disease and diseases caused by inflammation.

More... »

The CenterWatch Monthly, November 2011

Tuesday, November 1, 2011 02:05 PM

CRAs see role evolving into quality, compliance, start-up

More... »

AgonOx, MedImmune partner to develop cancer therapies

Monday, October 31, 2011 11:57 AM

AgonOx has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.

More... »

Trizzino joins Immunovaccine as CEO

Monday, September 12, 2011 12:44 PM

Immunovaccine has named John J. Trizzino chief executive officer, effective October 1, 2011. Trizzino will also be appointed to the company's board of directors.

More... »

CRO Cetero appoints James Dixon as SVP

Tuesday, April 26, 2011 02:07 PM

North Carolina-based CRO Cetero Research has appointed James "Jay" Dixon to senior vice president, quality and compliance. Dixon has spent more than 25 years in the pharmaceutical, biotechnology and CRO industries.  

More... »

Novavax appoints Stanley C. Erck as president and CEO

Wednesday, April 20, 2011 12:02 PM

Novavax’s Stanley C. Erck, its former executive chairman, has been appointed to the position of president and chief executive officer and will remain as a member of the board of directors. Current board member James Young, Ph.D., will assume the position of chairman of the board.

More... »

Manning, Chang new appointments at Aileron

Tuesday, April 12, 2011 12:35 PM

CAMBRIDGE, Mass.-based Aileron Therapeutics, a biopharmaceutical company that has developed a new class of drugs called stapled peptides, has appointed Anthony M. Manning, Ph.D., to senior vice president of research and preclinical development and Yong S. Chang, Ph.D., to head of biology.

More... »